Early failure of eculizumab in a patient with malignant atrophic papulosis: Is it time for initial combination therapy of eculizumab and treprostinil?

J Dermatol. 2020 Jan;47(1):e22-e23. doi: 10.1111/1346-8138.15120. Epub 2019 Oct 20.

Authors

Jerome Razanamahery¹, Camille Payet-Revest¹, Adrien Mareschal², Ines Saizonou³, Louise Bonnet⁴, Helder Gil¹, Sebastien Humbert¹, Nadine Magy-Bertrand¹

Affiliations

¹ Department of Internal Medicine, Besancon University Hospital, Besancon, France.
² Department of Dermatology, Besancon University Hospital, Besancon, France.
³ Department of Pathology, Besancon University Hospital, Besancon, France.
⁴ Department of Neurology, Besancon University Hospital, Besancon, France.

PMID: 31631389
DOI: 10.1111/1346-8138.15120

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Anticoagulants / therapeutic use
Cerebral Hemorrhage / diagnostic imaging
Cerebral Hemorrhage / etiology
Combined Modality Therapy
Complement Inactivating Agents / therapeutic use*
Epoprostenol / analogs & derivatives*
Epoprostenol / therapeutic use
Fatal Outcome
Glucocorticoids / therapeutic use
Humans
Intestinal Perforation / etiology
Male
Malignant Atrophic Papulosis / complications
Malignant Atrophic Papulosis / drug therapy*
Malignant Atrophic Papulosis / pathology
Prognosis
Prostaglandins, Synthetic / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Anticoagulants
Complement Inactivating Agents
Glucocorticoids
Prostaglandins, Synthetic
eculizumab
Epoprostenol
treprostinil